AI Article Synopsis
- Nitric oxide (NO) produced by synthase enzymes plays crucial roles in both benign and malignant human bladder tissues, with key pathways identified, such as NO/guanylate cyclase/cGMP and NO/oxidative pathways.
- Bladder carcinoma tissues from 18 patients and normal tissues from 8 patients were analyzed using immunohistochemistry, revealing stronger signaling for sGC and cGMP in malignant tissues, particularly in vascular endothelial and stromal cells.
- Findings suggest that NO influences bladder tissues through cGMP-mediated and non-cGMP-mediated effects, with increased nitrotyrosine levels indicating a notable difference between carcinoma and normal tissues.
Article Abstract
Background: Nitric oxide (NO) is produced by a group of synthase enzymes (NOS). By means of different pathways, NO exerts several functions in benign and malignant human bladder tissues. The current paper describes the NO/guanylate cyclase (sGC)/cyclic guanosine monophosphate (cGMP) and the NO/oxidative pathways in human bladder tissues.
Methods: Bladder carcinoma tissues were collected from 18 patients by transurethral resection procedures. Normal benign vesical tissue specimens from a further eight patients with benign diseases served as controls. Immunohistochemistry was conducted for localization of sGC, cGMP, and nitrotyrosine in benign and malignant vesical tissues, evaluating two-three tissue sections per patient.
Results: Positive immunolabeling for sGC and cGMP was detected in vascular endothelial cells of normal and malignant vesical tissues. Those signals were most intense in bladder carcinoma tissues. Immunolabeling for sGC and cGMP was also detected in normal urothelial cells. In bladder carcinoma cells, a heterogeneous immunolabeling for sGC and cGMP was seen, with a wide spectrum of signal intensity. Positive immunostaining for sGC and cGMP was also observed in stromal round cells in benign and malignant bladder tissues. Immunolabeling for nitrotyrosine was mainly observed in endothelial cells, with a much stronger immunolabeling in bladder carcinoma tissues compared to normal benign controls. A weak immunolabeling for nitrotyrosine was also observed in bladder carcinoma cells. Normal urothelial cells did not show such nitrotyrosine expression.
Conclusions: The current report provides evidences that NO play several roles through different pathways in benign and malignant vesical tissues. The influences generated by NO molecules can be divided into cGMP-mediated effects (those resulting from the NO/sGC/cGMP pathway) and non-cGMP-mediated effects (those resulting from the NO/oxidative pathway). Increased angiogenesis is a cGMP-mediated effect, while nitrotyrosine production is a non cGMP-mediated oxidative effect. Such an NO/oxidative pathway is observed more often in bladder carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/cncr.10942 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Rare Case of Bladder Melanosis: A Case Report and Review of the Literature.
Cureus
December 2024
Urology, Rotherham District General Hospital, Rotherham, GBR.
Bladder melanosis is a rare and poorly understood condition involving melanin pigmentation within the urothelial mucosa. Cases often present with haematuria, urinary obstructive symptoms, or cystitis. While generally considered benign, its potential association with malignancy warrants regular monitoring, as cases have previously been reported of an association with urothelial carcinoma and melanoma, although it is unclear whether there is a causal relationship.
View Article and Find Full Text PDFThick-walled Gallbladder: A Pragmatic Management Approach.
Euroasian J Hepatogastroenterol
December 2024
Department of General and Minimal Invasive Surgery, Sher-I-Kashmir Institute of Medical Sciences Soura, Srinagar, Jammu and Kashmir, India.
Introduction: Thick-walled gallbladder (TWGB) is a common yet non-specific radiological finding associated with a wide range of gallbladder pathologies, including acute and chronic inflammation, infection, and malignancy. Among the inflammatory causes, xanthogranulomatous cholecystitis (XGC) is a rare but significant condition that often mimics gallbladder carcinoma. This paper presents a pragmatic approach to the diagnosis and management of TWGB, focusing on the complexities posed by XGC.
View Article and Find Full Text PDFImmediate second resection versus restage transurethral resection of bladder tumor: A prospective randomized clinical trial (IMMERSE trial).
Urol Oncol
January 2025
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.
Background: The role of repeat transurethral resection of bladder tumor (TURBT) for the management of nonmuscle invasive bladder carcinoma is debated, especially when initial resections include detrusor muscle. This study compares immediate second resection (additional deep biopsies in the same session) with standard restage TURBT performed 2-6 weeks post-initial TURBT to determine adequacy in detrusor muscle sampling and compare the disease rate at restage TURBT in both groups.
Material And Methods: A randomized trial was conducted at a tertiary care hospital, including patients aged ≥18 years undergoing TURBT with complete primary tumor resection.
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
Clin Genitourin Cancer
December 2024
Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address:
Background: FGFR2/3, MTAP and ERBB2 genomic alterations have treatment targets in advanced urothelial carcinoma (aUC). These alterations may affect tumor microenvironment and outcomes with immune checkpoint inhibitors (ICIs) in aUC.
Patients And Methods: We identified patients with available genomic data in our multi-institution cohort of patients with aUC treated with ICI.
Feasibility and Oncological Outcome of Patients Achieving Noninvasive Downstaging After Transurethral Resection of Bladder Tumor Plus Systemic Chemotherapy for Bladder Preservation Strategy in Muscle-Invasive Bladder Cancer.
Clin Genitourin Cancer
December 2024
Department of Urology, Mie University hospital, Tsu, Japan.
Article Synopsis
- The study aimed to assess the outcomes of bladder preservation therapy combining maximal TURBT and neoadjuvant chemotherapy in muscle-invasive bladder cancer patients.
- A total of 110 patients were treated, with 61 achieving noninvasive downstaging, allowing them to preserve their bladders.
- The findings indicated that bladder preservation therapy had comparable survival rates to radical cystectomy, but more research is necessary to confirm these results due to the retrospective nature of the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!